Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Status:
Completed
Trial end date:
2009-01-02
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune
system and stop tumor cells from growing.
PURPOSE: This phase II trial is studying how poly-ICLC works in treating patients with
recurrent, progressive, or relapsed anaplastic glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins